Atlas Trials

Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS

Clinical trial NCT06050941 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06050941
Sponsor
First Affiliated Hospital of Zhejiang University
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Start date
2024-04-02
Primary completion
2026-04-02
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.